Palo Alto Investors LP
13F Reported Value
ⓘ$723.7M
Holdings
52
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Palo Alto Investors LP disclosed 52 positions worth $723.7M in its Form 13F-HR for Q2 2026, led by $PTCT (PTC THERAPEUTICS, INC.) at 10.4% of the equity portfolio, followed by $ACHC and $INSM. During the quarter the fund opened 4 new positions and exited 3 — including a new stake in $ACHC and a full exit from $ACAD. The portfolio is most concentrated in Healthcare (98.2% of disclosed assets). All figures are sourced directly from Palo Alto Investors LP’s Form 13F-HR filing with the SEC under CIK 1306923.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 35.4#2,306
Quality
$75.0M918,846 sh - 36.7#2,260
Quality
$72.5M2,864,096 sh - 39.4#2,150
Quality
$44.1M413,980 sh - 35.0
Quality
$40.8M348,808 sh - 48.4
Quality
$40.7M603,489 sh - 58.2
Quality
$39.1M682,777 sh - —
Quality
$36.6M1,647,521 sh - 71.3
Quality
$33.9M62,587 sh - —
Quality
$30.5M416,646 sh - 64.7
Quality
$30.3M140,279 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 PTC THERAPEUTICS, INC.$PTCT | 35.4#2,306 | $75.0M | 918,846 |
 Acadia Healthcare Company, Inc.$ACHC | 36.7#2,260 | $72.5M | 2,864,096 |
 INSMED Inc$INSM | 39.4#2,150 | $44.1M | 413,980 |
 Mirum Pharmaceuticals, Inc.$MIRM | 35.0 | $40.8M | 348,808 |
 ANAPTYSBIO, INC$ANAB | 48.4 | $40.7M | 603,489 |
 BIOMARIN PHARMACEUTICAL INC$BMRN | 58.2 | $39.1M | 682,777 |
 Dyne Therapeutics, Inc.$DYN | — | $36.6M | 1,647,521 |
 UNITED THERAPEUTICS Corp$UTHR | 71.3 | $33.9M | 62,587 |
 Disc Medicine, Inc.$IRON | — | $30.5M | 416,646 |
 BIOGEN INC.$BIIB | 64.7 | $30.3M | 140,279 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Palo Alto Investors LP's 52 positions.
Showing top 10 of 52 holdings.
Sector Allocation
Healthcare
$710.3M
Other
$11.2M
Financials
$2.2M
Full Holdings — Palo Alto Investors LP (Q2 2026)
All 52 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PTCT | PTC THERAPEUTICS, INC. | $75.0M | 10.4% | -0% | 35.4 |
| 2 | $ACHC | Acadia Healthcare Company, Inc. | $72.5M | 10.0% | NEW | 36.7 |
| 3 | $INSM | INSMED Inc | $44.1M | 6.1% | -0% | 39.4 |
| 4 | $MIRM | Mirum Pharmaceuticals, Inc. | $40.8M | 5.6% | +7% | 35 |
| 5 | $ANAB | ANAPTYSBIO, INC | $40.7M | 5.6% | -5% | 48.4 |
| 6 | $BMRN | BIOMARIN PHARMACEUTICAL INC | $39.1M | 5.4% | -0% | 58.2 |
| 7 | $DYN | Dyne Therapeutics, Inc. | $36.6M | 5.1% | -0% | — |
| 8 | $UTHR | UNITED THERAPEUTICS Corp | $33.9M | 4.7% | -0% | 71.3 |
| 9 | $IRON | Disc Medicine, Inc. | $30.5M | 4.2% | +4% | — |
| 10 | $BIIB | BIOGEN INC. | $30.3M | 4.2% | -0% | 64.7 |
| 11 |  $IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $22.0M | 3.0% | -17% | 36.8 |
| 12 |  $RARE | Ultragenyx Pharmaceutical Inc. | $19.9M | 2.8% | +0% | 34.2 |
| 13 |  $NVCR | NovoCure Ltd | $19.4M | 2.7% | +0% | — |
| 14 |  $SNDX | Syndax Pharmaceuticals Inc | $18.9M | 2.6% | +0% | 33.8 |
| 15 |  $ANNX | Annexon, Inc. | $16.8M | 2.3% | +0% | — |
| 16 |  $BCAX | Bicara Therapeutics Inc. | $16.3M | 2.3% | +0% | — |
| 17 |  $CDNA | CareDx, Inc. | $15.2M | 2.1% | +0% | 67.5 |
| 18 |  $CLDX | Celldex Therapeutics, Inc. | $14.9M | 2.1% | +35% | 8.4 |
| 19 |  $CMPX | Compass Therapeutics, Inc. | $12.8M | 1.8% | +285% | 28.1 |
| 20 |  $ALKS | Alkermes plc. | $12.7M | 1.8% | +0% | — |
| 21 |  $TRAX | First Tracks Biotherapeutics, Inc. | $12.1M | 1.7% | NEW | — |
| 22 | — | PROTHENA CORP PLC - SHS | $11.2M | 1.6% | -5% | — |
| 23 |  $TVTX | Travere Therapeutics, Inc. | $9.5M | 1.3% | -27% | 56.6 |
| 24 |  $TSHA | Taysha Gene Therapies, Inc. | $9.5M | 1.3% | +0% | 4.9 |
| 25 |  $ACRS | Aclaris Therapeutics, Inc. | $8.5M | 1.2% | +0% | 12 |
| 26 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $7.9M | 1.1% | +0% | 26.9 |
| 27 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $5.5M | 0.8% | +0% | 13.6 |
| 28 |  $ALGN | ALIGN TECHNOLOGY INC | $5.3M | 0.7% | -24% | 58.9 |
| 29 |  $ORKA | Oruka Therapeutics, Inc. | $3.2M | 0.4% | -44% | — |
| 30 |  $XENE | Xenon Pharmaceuticals Inc. | $3.1M | 0.4% | +0% | 24 |
| 31 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $3.1M | 0.4% | +0% | 76.5 |
| 32 |  $EW | Edwards Lifesciences Corp | $3.0M | 0.4% | +0% | 69.4 |
| 33 |  $STOK | Stoke Therapeutics, Inc. | $2.8M | 0.4% | +0% | 24.9 |
| 34 |  $CYTK | CYTOKINETICS INC | $2.7M | 0.4% | +0% | 28.1 |
| 35 |  $PYXS | Pyxis Oncology, Inc. | $2.6M | 0.4% | -14% | 16 |
| 36 |  $EHTH | eHealth, Inc. | $2.2M | 0.3% | +0% | 52.8 |
| 37 |  $CRSP | CRISPR Therapeutics AG | $2.2M | 0.3% | +0% | 9.7 |
| 38 |  $SGMT | Sagimet Biosciences Inc. | $1.9M | 0.3% | NEW | — |
| 39 |  $NUVB | Nuvation Bio Inc. | $1.9M | 0.3% | -36% | 37.9 |
| 40 |  $BNTX | BioNTech SE | $1.8M | 0.3% | +0% | — |
| 41 |  $CMPS | COMPASS Pathways plc | $1.6M | 0.2% | +0% | — |
| 42 |  $HUM | HUMANA INC | $1.6M | 0.2% | +0% | 58.9 |
| 43 |  $NAMS | NewAmsterdam Pharma Co N.V. | $1.5M | 0.2% | NEW | — |
| 44 |  $VSTM | Verastem, Inc. | $1.2M | 0.2% | +26% | 29.7 |
| 45 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $959,530 | 0.1% | +0% | 40.7 |
| 46 |  $URGN | UroGen Pharma Ltd. | $901,600 | 0.1% | +0% | — |
| 47 |  $BCYC | BICYCLE THERAPEUTICS PLC | $856,014 | 0.1% | +0% | — |
| 48 |  $XERS | Xeris Biopharma Holdings, Inc. | $826,927 | 0.1% | +0% | 56.5 |
| 49 |  $ABEO | ABEONA THERAPEUTICS INC. | $672,786 | 0.1% | +0% | 23.7 |
| 50 |  $INSP | Inspire Medical Systems, Inc. | $391,319 | 0.1% | +0% | 63.7 |
| 51 |  $PRQR | ProQR Therapeutics N.V. | $351,181 | 0.1% | +0% | — |
| 52 |  $ALDX | Aldeyra Therapeutics, Inc. | $331,660 | 0.1% | +0% | — |
New Positions (4)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Palo Alto Investors LP including:
Track Palo Alto Investors LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Palo Alto Investors LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Palo Alto Investors LP
13F Pro is an AI hedge fund tracker and stock research platform. For Palo Alto Investors LP (SEC CIK: 1306923), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Palo Alto Investors LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.